# OnCo record john-seymour (person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/people/john-seymour/>
  a schema:Person ;
  onco:kind "person" ;
  schema:identifier "john-seymour" ;
  schema:name "John F. Seymour"@en ;
  schema:description "Led MURANO, which established venetoclax plus rituximab as fixed-duration therapy for relapsed CLL."@en ;
  schema:url <https://onco.cc/people/john-seymour/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/?term=Seymour%20JF%5BAuthor%5D%20venetoclax%20MURANO> ;
  onco:tag "cll", "venetoclax", "australia" ;
  schema:jobTitle "Director of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital" ;
  schema:sameAs <https://orcid.org/0000-0003-2188-6835> ;
  onco:cancers <https://onco.cc/cancers/cll/> ;
  onco:technologies <https://onco.cc/technologies/mrd-testing/> ;
  onco:targets <https://onco.cc/targets/bcl2/>, <https://onco.cc/targets/cd20/> ;
  onco:drugs <https://onco.cc/drugs/venetoclax/> ;
  onco:institutions <https://onco.cc/institutions/peter-mac/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-murano-venetoclax-rituximab-nejm-2018/> ;
  schema:affiliation <https://onco.cc/institutions/peter-mac/> .